What We're Reading: Page
Industry reads hand-picked by our editors
Feb 07, 2019
-
Reuters
Novartis CEO lauds Trump administration plan to overhaul rebates
-
USA Today
Trump's border wall won't solve addiction crisis — but finally targeting big pharma can
-
Boston Business Journal
Here are the largest Series A rounds in Mass. biotech
-
STAT
Cancer treatment at home is closer to happening than you think
Feb 06, 2019
-
Politico
Democrats bat away Trump's olive branch on drug pricing
-
The Guardian
Self-regulation by the pharmaceutical industry isn't working, say experts
-
BioCentury
Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations
-
Financial Times
Chinese biotech feels chill in harsh winter for venture capital
Feb 05, 2019
-
Undark
Policing big pharma's influence over doctors' treatment guidelines
-
Boston Business Journal
$100 per square foot for biotech lab space? It could soon be coming to Cambridge
-
Medical Marketing & Media
How pharma is tightening up data privacy and security
-
The Hill
Ocasio-Cortez fires back at critic who called her drug industry knowledge 'inadequate'
Feb 04, 2019
-
CNBC
Bristol-Myers Squibb shares pop on report Starboard Value has taken a stake in the drugmaker
-
Vantage
The list of shame no biopharma wants to join
-
Kaiser Health News
Winners And Losers Under Bold Trump Plan To Slash Drug Rebate Deals
-
STAT
As cystic fibrosis drugs deliver new hope, progress isn't reaching everyone
Feb 01, 2019
-
Bloomberg
The $4.3 Billion Deal That Blew Up Over Shoddy Drug Production
-
Business Insider
FDA warned of EpiPen complaint problems at Pfizer's Meridian factories
-
The New York Times
Shortage of anxiety drug leaves patients scrambling
-
BioCentury
Parliament to debate compulsory licensing of Vertex's Orkambi
Jan 31, 2019
-
CNN
Opioid maker Purdue Pharma fights to prevent documents involving Sackler family from going public
-
The Boston Globe
Charlie Baker takes on big pharma
-
The New York Times
Was C.T.E. stealing his mind? A gunshot provided the answer
-
The Wall Street Journal
Pharma investors, pick your poison
Jan 30, 2019
-
Vantage
Following the M&A money, by phase and therapy area
-
The New York Times
On Both Ends of Capitol, Both Parties Warn Big Pharma on Drug Prices
-
S&P Global Market Intelligence
US FDA back in business after shutdown, but regulatory work has 'piled up'
-
Healthcare Dive
Anthem accelerates launch of PBM IngenioRx
Previous
